Short Interest in Inogen, Inc. (NASDAQ:INGN) Decreases By 16.6%

Inogen, Inc. (NASDAQ:INGN) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 665,900 shares, a drop of 16.6% from the January 31st total of 798,600 shares. Currently, 3.2% of the company’s stock are sold short. Based on an average trading volume of 246,200 shares, the days-to-cover ratio is currently 2.7 days.

Inogen Trading Up 2.1 %

NASDAQ INGN traded up $0.17 during mid-day trading on Wednesday, reaching $8.20. 294,093 shares of the company’s stock traded hands, compared to its average volume of 314,666. The company has a fifty day simple moving average of $10.16 and a 200-day simple moving average of $10.11. Inogen has a 1-year low of $6.14 and a 1-year high of $13.33. The company has a market cap of $195.36 million, a price-to-earnings ratio of -3.62 and a beta of 1.02.

Wall Street Analyst Weigh In

INGN has been the topic of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Wednesday, February 26th. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently made changes to their positions in INGN. AlphaQuest LLC bought a new position in Inogen during the 4th quarter valued at $43,000. Meeder Asset Management Inc. bought a new position in shares of Inogen during the fourth quarter worth about $56,000. Quarry LP acquired a new position in Inogen in the third quarter worth about $59,000. Integrated Quantitative Investments LLC bought a new stake in Inogen in the fourth quarter valued at about $92,000. Finally, Ieq Capital LLC acquired a new stake in Inogen during the fourth quarter valued at approximately $94,000. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.